A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf (Astellas)While the incidence of acute rejection and early graft loss have improved dramatically with the advent of newer immunosuppressant medications, improvements in long-term patient and allograft survival after kidney transplantation have not been achieved.Recruiting Principal Investigator Jagbir GillBody Locations and Systems Kidney TransplantationArea VancouverAge 19 and above
Pilot Clinical Trial of Ustekinumab in Patients With New-onset T1D (UST1D)In type 1 diabetes (T1D), immune defense cells in the body attack and destroy insulin-producing beta cells leaving affected people with a lifelong need for daily insulin injections.Recruiting Principal Investigator Thomas G. ElliottBody Locations and Systems Diabetes - Type 1Area VancouverAge 18-35
Hypoglycemia (Low Blood Sugar) and the HeartThe risk of hypoglycemia (low blood sugar) associated with the treatment of diabetes increases with age. Hypoglycemia is a common reason for admission to hospital for older patients with diabetes.Recruiting Principal Investigator Graydon S. MeneillyBody Locations and Systems Diabetes - Type 2Area VancouverAge 70 and above
Trientine Hydrochloride for the Prevention of Macular Edema After Cataract Surgery in Patients With Type 2 Diabetes MellitusThe primary purpose of the protocol is to evaluate whether Trientine Hydrochloride, a copper chelator which is an agent that binds with and removes copper, will be effective in minimizing macular edema after cataract surgery in individuals with type 2 diabetes.Recruiting Principal Investigator David MaberleyBody Locations and Systems Macular Edema, Diabetes - Type 2Area VancouverAge 19 and above
From Clinic to Community Study (C2C)This study is a 12-month study. There are two different groups in the study. Both groups will enter the study after the graduation from 8-hour diabetes education course taught at VGH, St. Paul's, or Richmond Hospital.Recruiting Principal Investigator Tricia TangBody Locations and Systems Diabetes - Type 2Area VancouverAge 21 and above
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03The purpose of this study is to compare the efficacy of relamorelin with that of placebo in participants with diabetic gastroparesis (DG). At the end of the 40-week Treatment Period, participants will either continue on relamorelin or placebo for 6 additional weeks. Recruiting Principal Investigator Nazira ChaturBody Locations and Systems Diabetes - Type 1, Diabetes - Type 2Area VancouverAge 18 and above
BLADE-PCI Trial (BLADE); PHASE IIB LIPOSOMAL ALENDRONATE STUDY (BLADE)The main objective of this study is to assess the safety, efficacy and dose response of LABR-312 administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent in reducing restenosis as measured by Optical Coherence Tomography (OCT) at 9 months post pRecruiting Principal Investigator David WoodBody Locations and Systems Diabetic Heart DiseaseArea VancouverAge 18 and above
Diabetic Retinopathy and Subclinical Signs of Disease Transition (DIRECTION)The purpose of this study is to quantify and follow the retinal layer thickness and capillary density in patients that are in a critical period of disease transition to better understand the process of diabetic retinopathy. Recruiting Principal Investigator David MaberleyBody Locations and Systems Diabetic Eye ProblemsArea VancouverAge 18-90
Glucose Variability in Subclinical HypertrophyEvaluation of insulin absorption at sites affected by clinically apparent lipohypertrophy through short-term continuous glucose monitoring has shown inconsistent results and it is yet unknown how or if subclinical lipohypertrophy affects absorption.Recruiting Principal Investigator Graydon S. MeneillyBody Locations and Systems Diabetes - Type 1, Diabetes - Type 2Area VancouverAge 19 and above
Bexagliflozin Efficacy and Safety Trial (BEST) The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM) and increased risk of cardiovascular adverse events.Recruiting Principal Investigator G B John ManciniBody Locations and Systems Diabetes - Type 2Area VancouverAge 40 and above
Treatment for CI-DME in Eyes With Very Good VA Study (Protocol V)Although multiple studies have clearly demonstrated that ranibizumab therapy is more effective than laser alone for vision gain and avoiding vision loss in patients with central-involved Diabetic Macular Edema (DME), only eyes with poor visual acuity, such as a visual acuity letter score of 78 orClosed for Recruitment Principal Investigator David MaberleyBody Locations and Systems Macular EdemaArea VancouverAge 18 and above
Peripheral Diabetic Retinopathy (DR) Lesions on Ultrawide-field Fundus Images and Risk of DR Worsening Over Time To determine the association between peripheral diabetic retinopathy lesions and the likelihood of diabetic retinopathy worsening or improving over time. Closed for Recruitment Principal Investigator David MaberleyBody Locations and Systems Diabetic Eye Problems, Diabetes - Type 1, Diabetes - Type 2Area VancouverAge 18 and above
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE)The goal of this study is to assess whether canagliflozin has a renal and vascular protective effect in reducing the progression of renal impairment relative to placebo in participants with type 2 diabetes mellitus (T2DM), Stage 2 or 3 chronic kidney disease (CKD) and macroalbuminuria, who are reClosed for Recruitment Principal Investigator Nadia ZalunardoBody Locations and Systems Diabetic Kidney Problems, Diabetes - Type 2Area VancouverAge 30 and above
Effects of Sedentary Behaviour on Metabolic ParametersThe rates of sedentary activity are increasing. Studies have shown that time spent on doing sedentary activities is an independent risk factor for cardiovascular disease. Prior studies have shown that interrupting inactivity improved the body's handling of blood glucose and gene expression.Closed for Recruitment Principal Investigator Kenneth MaddenBody Locations and Systems Diabetes - Type 2Area VancouverAge 65 and above
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular…This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with CV disease and/or multiple CV risk factors. Closed for Recruitment Principal Investigator Graham WongBody Locations and Systems Diabetes - Type 2, Coronary Artery DiseaseArea VancouverAge 40 and above
